Activated platelet aggregation is transiently impaired also by a reduced dose of protamine

References

• Paparella D, Brister SJ, Buchanan MR. Coagulation disorders of cardiopulmonary bypass: a review. Intensive Care Med. 2004;30:1873–1881.
   PubMed Web of Science ®Google Scholar
• Samson S, Shore-Lesserson L. Platelet function and cardiopulmonary bypass. Semin Cardiothorac Vasc Anesth. 2001; 5:273–281.
   Google Scholar
• Harker LA. Bleeding after cardiopulmonary bypass. N Engl J Med. 1986; 314:1446–1448.
   PubMed Web of Science ®Google Scholar
• Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blood. 1990;76:1680–1697.
   PubMed Web of Science ®Google Scholar
• Kestin AS, Valeri CR, Khuri SF, et al. The platelet function defect of cardiopulmonary bypass. Blood. 1993;82:107–117.
   PubMed Web of Science ®Google Scholar
• Harker LA, Malpass TW, Branson HE, et al. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood. 1980;56:824–834.
   PubMed Web of Science ®Google Scholar
• Boer C, Meesters MI, Veerhoek D, et al. Anticoagulant and side-effects of protamine in cardiac surgery: a narrative review. Br J Anaesth. 2018;120:914–927.
   PubMed Web of Science ®Google Scholar
• Mclaughlin KE, Dunning J. In patients post cardiac surgery do high doses of protamine cause increased bleeding?. Interact Cardiovasc Thorac Surg. 2003;2:424–426.
   PubMedGoogle Scholar
• Carr ME, Jr, Carr SL. At high heparin concentrations, protamine concentrations which reverse heparin anticoagulant effects are insufficient to reverse heparin anti-platelet effects. Thromb Res. 1994;75:617–630.
   PubMed Web of Science ®Google Scholar
• Ellison N, Edmunds LH, Jr, Colman RW. Platelet aggregation following heparin and protamine administration. Anesthesiology. 1978;48:65–68.
   PubMed Web of Science ®Google Scholar
• Mochizuki T, Olson PJ, Szlam F, et al. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg. 1998;87:781–785.
   PubMed Web of Science ®Google Scholar
• Olsson A, Alfredsson J, Håkansson E, et al. Protamine reduces whole blood platelet aggregation after cardiopulmonary bypass. Scand Cardiovasc J. 2016;50:58–63.
   PubMed Web of Science ®Google Scholar
• Ammar T, Fisher CF. The effects of heparinase 1 and protamine on platelet reactivity. Anesthesiology. 1997;86:1382–1386.
   PubMed Web of Science ®Google Scholar
• Ural K, Owen C. Pro: The Hepcon HMS should be used instead of traditional activated clotting time (ACT) to dose heparin and protamine for cardiac surgery requiring cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2016;30:1727–1729.
   PubMed Web of Science ®Google Scholar
• Hällgren O, Svenmarker S, Appelblad M. Implementing a statistical model for protamine titration: effects on coagulation in cardiac surgical patients. J Cardiothorac Vasc Anesth. 2017;31:516–521.
   PubMed Web of Science ®Google Scholar
• Olsson A, Alfredsson J, Ramström S, et al. Better platelet function, less fibrinolysis and less hemolysis in re-transfused residual pump blood with the Ringer’s chase technique – a randomized pilot study. Perfusion. 2018;33:185–193.
   PubMed Web of Science ®Google Scholar
• Gertler R, Wiesner G, Tassani-Prell P, et al. Are the point-of-care diagnostics MULTIPLATE and ROTEM valid in the setting of high concentrations of heparin and its reversal with protamine?. J Cardiothorac Vasc Anesth. 2011;25:981–986.
   PubMed Web of Science ®Google Scholar
• Ortmann E, Klein AA, Sharples LD, et al. Point-of-care assessment of hypothermia and protamine-induced platelet dysfunction with multiple electrode aggregometry (Multiplate(R)) in patients undergoing cardiopulmonary bypass. Anesth Analg. 2013;116:533–540.
   PubMed Web of Science ®Google Scholar
• Khan NU, Wayne CK, Barker J, et al. The effects of protamine overdose on coagulation parameters as measured by the thrombelastograph. Eur J Anaesthesiol. 2010;27:624–627.
   PubMed Web of Science ®Google Scholar
• Ni Ainle F, Preston RJS, Jenkins PV, et al. Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation. Blood. 2009;114:1658–1665.
   PubMed Web of Science ®Google Scholar
• Barstad RM, Stephens RW, Hamers MJ, et al. Protamine sulphate inhibits platelet membrane glycoprotein Ib-von Willebrand factor activity. Thromb Haemost. 2000;83:334–337.
   PubMed Web of Science ®Google Scholar
• Ranucci M, Baryshnikova E, Soro G, et al. Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines. Ann Thorac Surg. 2011;91:123–129.
   PubMed Web of Science ®Google Scholar
• Gilly G, Trusheim J. Con: The Hepcon HMS should not be used instead of traditional activated clotting time to dose heparin and protamine for cardiac surgery requiring cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2016;30:1730–1732.
   PubMed Web of Science ®Google Scholar
• Kjellberg G, Sartipy U, van der Linden J, et al. An adjusted calculation model allows for reduced protamine doses without increasing blood loss in cardiac surgery. Thorac Cardiovasc Surg. 2016;64:487–493.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Wolf H-G, Sinzobahamvya N, et al. Prolonged activated clotting time after protamine administration does not indicate residual heparinization after cardiopulmonary bypass in pediatric open heart surgery. Thorac Cardiovasc Surg. 2015;63:397–403.
   PubMed Web of Science ®Google Scholar
• Griffin MJ, Rinder HM, Smith BR, et al. The effects of heparin, protamine, and heparin/protamine reversal on platelet function under conditions of arterial shear stress. Anesth Analg. 2001;93:20–27.
   PubMed Web of Science ®Google Scholar